Chemours

The Chemours Co. is a holding company, which engages in the provision of performance chemicals. The firm delivers solutions, which include a range of industrial and chemical products for markets including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and consumer electronics, and general industrial. It operates through the following segments: Titanium Technologies, Thermal and Specialized Solutions, Advanced Performance Materials, and Chemical Solutions. The Titanium Technologies segment is involved in the manufacture of titanium dioxide pigment. The Thermal and Specialized Solutions segment offers refrigerants, propellants, blowing agents, and specialty solvents. The Advanced Performance Materials segment produces polymers and advanced materials that deliver attributes, including chemical inertness, thermal stability, low friction, weather and corrosion resistance, extreme temperature stability, and di-electric properties. The Chemical Solutions segment refers to the sale of chemicals used in industrial and consumer applications in the Americas. The company was founded on February 18, 2014, and is headquartered in Wilmington, DE.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Chemours overcomes Q4 challenges, eyes growth and sustainability in 2023

Chemours had a tough Q4 but a successful year overall, with a focus on margin improvement, growth in key businesses, and addressing legacy issues. The company is optimistic about 2023, emphasizing sustainability-led growth and returning value to shareholders.

Chemours reports strong Q1 performance, navigates challenges, eyes growth opportunities

Chemours' Q1 2023 Earnings Call highlighted strong performance, reaffirmed guidance, and emphasized margin improvement strategies. The company faces challenges from macroeconomic uncertainties and inflationary pressures but sees opportunities in sustainable initiatives and market-led innovation. Chemours remains confident in its full-year outlook and growth strategies.

Chemours reports record results, eyes cost reduction and innovation

Chemours had a strong quarter with record results and notable achievements in facility closures and settlements. While challenges lie ahead with a weaker second half expected, the company remains focused on shareholder value and strategic priorities. Opportunities in cost reduction, innovation, and market leadership position Chemours for future growth.

Chemours addresses challenges, eyes growth in sustainable solutions market

Chemours Company navigated challenges in Q3 2023, with a focus on long-term shareholder value and strategic transformation for performance improvement.
Strong performance in Performance Solutions and TSS business, alongside cost savings initiatives, position Chemours for future growth and margin recovery.
Management's commitment to driving value for shareholders amidst industry challenges underscores a proactive approach to addressing market dynamics.

Chemours reports Q4 sales growth, addresses TiO2 market challenges

Chemours is navigating challenges in the TiO2 market while focusing on cost reduction and growth opportunities in other segments. The company aims to maintain competitiveness through strategic decisions and investments in R&D. Analysts' inquiries during the earnings call highlighted concerns about leadership stability and various segment dynamics.

Chemours reports mixed Q1 results, eyes sequential growth in 2024

Chemours' Q1 2024 performance reflected mixed results across segments, with a focus on cost efficiencies, transformation plans, and maintaining liquidity amidst declining net sales and EBITDA.
Despite challenges in certain segments and market uncertainties, Chemours remains optimistic about sequential growth in the second quarter, aiming for significant EBITDA potential in 2024 and long-term financial improvement.
Strategic strengths in cost management, growth initiatives, and market opportunities position Chemours to navigate challenges, drive growth, and enhance profitability in a dynamic business environment.

Chemours exceeds volume expectations amidst challenges, anticipates sequential decline

Chemours demonstrated resilience and growth in key product lines despite facing challenges in Q1 and Q2.
The company's cost-saving efforts and recovery in certain segments highlight its ability to adapt to market conditions.
While financial results were impacted by one-time costs and a decline in net sales, Chemours maintained a strong net leverage ratio.
Anticipated sequential decline in net sales for Q3 underscores the need for strategic planning and operational optimization.

Chemours reports strong Q3 performance amidst strategic growth initiatives

Chemours' Q3 performance reflects operational strength and growth in key segments.
Challenges include declines in net sales for TSS and TT in Q4 and a net loss.
Opportunities exist in cost savings, growth in Opteon refrigerants, and strategic investments.
Overall, Chemours remains confident in its strategy to drive shareholder value.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The Chemours Co. is a holding company, which engages in the provision of performance chemicals. The firm delivers solutions, which include a range of industrial and chemical products for markets including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and consumer electronics, and general industrial. It operates through the following segments: Titanium Technologies, Thermal and Specialized Solutions, Advanced Performance Materials, and Other. The Titanium Technologies segment is involved in the manufacture of titanium dioxide pigment. The Thermal and Specialized Solutions segment offers refrigerants, propellants, blowing agents, and specialty solvents. The Advanced Performance Materials segment produces polymers and advanced materials that deliver attributes, including chemical inertness, thermal stability, low friction, weather and corrosion resistance, extreme temperature stability, and di-electric properties. The Other segment consists of performance chemicals and intermediates business. The company was founded on February 18, 2014, and is headquartered in Wilmington, DE.

Chemical maker Chemours reported better-than-expected fourth-quarter earnings.

Chemours Stock Is Plunging Despite Earnings Beat. There Are Two Reasons.

NEW YORK, NY / ACCESSWIRE / March 28, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of The Chemours Company ("The Chemours Company") (NYSE:CC) concerning possible violations of federal securities laws. On February 13, 2024, after the market close, Chemours Co. announced that it would be delaying the release of Q4 and full year 2023 financial results as the Company evaluates its internal controls over financial reporting.

CC ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your The Chemours Company Investment

Chemours (CC) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.29 per share. This compares to break-even earnings per share a year ago.

Chemours (CC) Q4 Earnings Top Estimates

In its annual filing the company said that its lack of internal control was partially a result of senior management failing to set an appropriate tone, specifically related to the delayed payments.

Chemours Responds to Regulators, Prosecutors About Internal Audit

WILMINGTON, Del.--(BUSINESS WIRE)--The Chemours Company (“Chemours” or “the Company”) (NYSE: CC), a global chemistry company with leading market positions in Titanium Technologies (“TT”), Thermal & Specialized Solutions (“TSS”), and Advanced Performance Materials (“APM”), today announced that, as disclosed in the Company's Annual Report on Form 10-K filed today, March 27, 2024, the Audit Committee of the Board of Directors has completed its planned procedures with respect to the internal re.

Chemours Announces Completion of Planned Procedures by the Audit Committee with Respect to Internal Review

WILMINGTON, Del.--(BUSINESS WIRE)--The Chemours Company (“Chemours” or “the Company”) (NYSE: CC), a global chemistry company with leading market positions in Titanium Technologies (“TT”), Thermal & Specialized Solutions (“TSS”), and Advanced Performance Materials (“APM”), today announced its financial results for the fourth quarter and full year 2023. Key Fourth Quarter 2023 Results Net Sales of $1.4 billion, up 2% year-over-year Net Loss attributable to Chemours of $18 million, or a loss o.

The Chemours Company Reports Fourth Quarter and Full Year 2023 Results

NEW YORK , March 27, 2024 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of The Chemours Company (NYSE: CC) between February 10, 2023 and February 28, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages The Chemours Company Investors to Secure Counsel Before Important Deadline in Securities Class Action - CC

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired The Chemours Company (“Chemours” or the “Company”) (NYSE: CC) common stock between February 10, 2023 and February 28, 2024, inclusive (the “Class Period”). Chemours investors have until May 20, 2024 to file a lead plaintiff motion. If you suffered a loss on your Chemo.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of The Chemours Company (CC) Investors

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Chemours (CC) a Great Value Stock Right Now?

SAN DIEGO , March 27, 2024 /PRNewswire/ -- DiCello Levitt LLP announces that purchasers or acquirers of The Chemours Company ("Chemours" or the "Company") (NYSE: CC) common stock between February 10, 2023 and February 28, 2024, inclusive (the "Class Period"), have until May 20, 2024 to seek appointment as lead plaintiff of the Chemours class action lawsuit. The Chemours lawsuit charges the Company, certain senior executive officers, and the Company's underwriters with violations of the federal securities laws.

DICELLO LEVITT LLP ANNOUNCES INVESTOR CLASS ACTION LAWSUIT FILED AGAINST THE CHEMOURS COMPANY (NYSE: CC) AND LEAD PLAINTIFF DEADLINE

LOS ANGELES, CA / ACCESSWIRE / March 27, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against The Chemours Company ("Chemours" or "the Company") (NYSE:CC) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 10, 2023 and February 28, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before May 20, 2024.

DEADLINE ACTION ALERT: The Schall Law Firm Encourages Investors in The Chemours Company with Losses of $100,000 to Contact the Firm

NEW YORK, NY / ACCESSWIRE / March 26, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of The Chemours Company ("The Chemours Company") (NYSE:CC) concerning possible violations of federal securities laws. On February 13, 2024, after the market close, Chemours Co. announced that it would be delaying the release of Q4 and full year 2023 financial results as the Company evaluates its internal controls over financial reporting.

The Chemours Company Being Investigated on Behalf of The Chemours Company Investors. Contact Levi & Korsinsky For Details

WILMINGTON, Del.--(BUSINESS WIRE)---- $CC--Chemours Announces Dates for Fourth Quarter 2023 Earnings Release, 2023 Form 10-K Filing and Webcast Conference Call.

Chemours Announces Dates for Fourth Quarter 2023 Earnings Release, 2023 Form 10-K Filing and Webcast Conference Call

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased The Chemours Company (“Chemours” or the “Company”) (NYSE: CC) common stock between February 10, 2023 and February 28, 2024, inclusive (the “Class Period”). Chemours investors have until May 20, 2024 to file a lead plaintiff motion. Investors suffering losses on their Chemours investments are encouraged to contact the Law Offices of Howard G. Sm.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of The Chemours Company (CC) Investors

Shareholders that Lost Money on The Chemours Company(CC) Should Contact Levi & Korsinsky about Securities Fraud Investigation - CC

Shareholder Rights Advocates at Levi & Korsinsky Investigate The Chemours Company (CC) Regarding Possible Securities Fraud Violations

LOS ANGELES, CA / ACCESSWIRE / March 26, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against The Chemours Company ("Chemours" or "the Company") (NYSE:CC) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between February 10, 2023 and February 28, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before May 20, 2024.

DEADLINE ACTION REMINDER: The Schall Law Firm Encourages Investors in The Chemours Company with Losses of $100,000 to Contact the Firm

SAN DIEGO--(BUSINESS WIRE)---- $CC #FreeCashFlow--Robbins LLP is Investigating the Allegations that The Chemours Company (CC) Had Deficient Accounting Practices and Procedures.

The Chemours Company (CC) Stockholder Alert: Robbins LLP Reminds Investors of Class Action Filed Against The Chemours Company

NEW YORK, NY / ACCESSWIRE / March 25, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of The Chemours Company ("The Chemours Company") (NYSE:CC) concerning possible violations of federal securities laws. On February 13, 2024, after the market close, Chemours Co. announced that it would be delaying the release of Q4 and full year 2023 financial results as the Company evaluates its internal controls over financial reporting.

The Chemours Company Investigated by Shareholder Rights Advocates – Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - CC

SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Chemours business and prospects, resulting in its stock trading at inflated prices.

CC INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that The Chemours Company Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

LOS ANGELES, CA / ACCESSWIRE / March 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of The Chemours Company ("Chemours" or "the Company") (NYSE:CC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against The Chemours Company and Encourages Investors with Losses to Contact the Firm

RADNOR, Pa. , March 24, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that today the firm has filed a securities fraud class action lawsuit against The Chemours Company (NYSE: CC) ("Chemours" or the "Company") on behalf of investors who purchased or acquired Chemours common stock between February 10, 2023 and February 28, 2024, inclusive (the "Class Period").

CLASS ACTION ANNOUNCEMENT (CC): Kessler Topaz Meltzer & Check, LLP Has Filed A Securities Fraud Class Action Lawsuit Against The Chemours Company

SAN DIEGO , March 23, 2024 /PRNewswire/ --  Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of The Chemours Company (NYSE: CC) common stock have until May 20, 2024 to seek appointment as lead plaintiff of the Chemours class action lawsuit. Captioned Taylor v.

CC INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that The Chemours Company Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

RADNOR, Pa. , March 22, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that today the firm has filed a securities fraud class action lawsuit against The Chemours Company (NYSE: CC) ("Chemours" or the "Company") on behalf of investors who purchased or acquired Chemours common stock between February 10, 2023 and February 28, 2024, inclusive (the "Class Period").

KESSLER TOPAZ MELTZER & CHECK, LLP HAS FILED A SECURITIES FRAUD CLASS ACTION LAWSUIT AGAINST THE CHEMOURS COMPANY

Dignam had been serving as interim CEO since the chemical company put its top executives on leave last month amid an accounting investigation.

News for Chemours Stock (CC)